AI-Powered Drug Design Program
Deargen streamlines the initial R&D stage of new drug development with A.I. Each of Deargen's programs focuses on diseases with high medical demands, such as anticancer drugs, cardiovascular and metabolic diseases, neurological diseases, and immune diseases.
Oncology
CVRM
Neurology
Immunology
4D Program
The 4D (Deargen-Driven Drug Development) program is a new drug development pipeline led by Deargen from the discovery of Hit substances. Using A.I, we develop optimal new drug candidates through the iterative process of prediction, synthesis, validation, and re-learning.
DG-ONCO-T1
DG-ONCO-T2
DG-ONCO-T3
DG-ONCO-T4
DG-HF-T1
DG-HL-T1
DG-ALS-T1
Co-Developed Program
Deargen is developing new drugs through various cooperation with domestic and overseas drug developers.
NASH - Target1
NASH - Target2
NASH - Target3
IPF - Target1
IPF - Target2
IPF - Target3
IPF - Target4
Oncology
Immunology
Hearing Loss
ALZHEIMER’s - Target1
ALZHEIMER’s - Target2
ALZHEIMER’s - Target3
ALZHEIMER’s - Target4
ALZHEIMER’s - Target4
oncology
oncology
Service Agreement
oncology
Service Agreement